CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$1.81 + 0.01 (0.56%)
Day High:$1.85
Day Low:$1.79
03/27/154:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345

CTI Life Sciences Limited, Milan Branch
Laura Villa
T +1 39 02 94751572
T +1 206-272-4155 (U.S. only)

Recent News

Mar 16, 2015CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of ... 
Printer Friendly Version
Mar 12, 2015CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results
- Positive Top-Line Results from PERSIST-1 Phase 3 Study of Pacritinib in Patients with Myelofibrosis - - PIXUVRI Receives Reimbursement in Spain - - Total Revenues for Full Year 2014 Reach $60.1 Million - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, March 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014. "In 2014, we successfully accomp... 
Printer Friendly Version
Mar 09, 2015CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis
Trial Meets Primary Endpoint in Intent-to-Treat Population Oral Pacritinib is the First Agent with Clinical Data Supporting its Use in Treating Patients with Myelofibrosis Irrespective of Their Platelet Count, Including Severe and Life-Threatening Thrombocytopenia (low platelets) CTI BioPharma to Host Conference Call Today at 8:00 am EDT SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (... 
Printer Friendly Version


Mar 12, 2015
Q4 2014 CTI BioPharma Corp Earnings Conference Call
Mar 09, 2015
CTI BioPharma Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.